ALK and non-small cell lung carcinoma: Thus, rebiopsy in ALK‐TKI‐refractory patients has attracted increasing attention as it assists in determining optimal treatment strategy; however, it is unclear whether or not rebiopsy should be performed to improve the prognosis of the ALK‐positive NSCLC patients.